[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595363":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":26,"responsibleParty":43,"collaborators":26,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":26,"enrollmentInfo":55,"targetDuration":26,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":68,"whyStopped":26,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":26},{"fullName":5,"class":6},"Chulalongkorn University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Itopride","EXPERIMENTAL","Enteral Itopride (50 mg enterally tid ac)",[13],"Drug: Itopride HCI 50 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Metoclopramide","ACTIVE_COMPARATOR","Intravenous Metoclopramide (10 mg IV q 6 hours)\n\nCrCl 15-60 ml\u002Fmin: Metoclopramide 5 mg IV q 6 hours CrCl \\\u003C15 ml\u002Fmin: Metoclopramide 5 mg IV q 12 hours Hepatic impairment\u002F cirrhosis: Metoclopramide 5 mg IV q 6 hours",[19],"Drug: Metoclopramide 10 mg ampoule",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Itopride HCI 50 mg","Enteral Itopride 50 mg enterally tid ac",[9],null,{"type":22,"name":28,"description":17,"armGroupLabels":29,"otherNames":26},"Metoclopramide 10 mg ampoule",[15],[31],{"name":32,"affiliation":5,"role":33},"Narisorn Lakananurak, MD.","STUDY_DIRECTOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":26,"email":39},"Sasicha Kitphati, MD.","CONTACT","+66819244809","kitphati.s@gmail.com",{"name":32,"role":37,"phone":41,"phoneExt":26,"email":42},"+66853347979","Narisorn.l@chula.ac.th",{"type":44,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100595363","phase-4-efficacy-of-itopride-versus-metoclopramide-in-hospitalized-medicine-patients-with-high-gastric-residual-volume-100595363",false,"NCT07031479","Efficacy of Itopride Versus Metoclopramide in Hospitalized Medicine Patients With High Gastric Residual Volume","Efficacy of Enteral Itopride Versus Intravenous Metoclopramide in Hospitalized Medicine Patients With Feeding Intolerance Causing by High Gastric Residual Volume: a Prospective Randomized Controlled Trial","GRV","Inclusion Criteria:\n\n* Hospitalized medical patients aged over 18 years who were receiving enteral feeding and had a gastric residual volume (GRV) ≥ 200 ml\n\nExclusion Criteria:\n\n* Use of any prokinetic drug within 24 hours before participating in the study\n* Known hypersensitivity or contraindication to Metoclopramide or Itopride\n* Prolonged QTc interval \\> 460 ms in female \\>440 ms in male\n* Hemodynamic instability\n* GI surgery ≤ 6 weeks before enrollment in the study\n* History of esophagectomy or gastrectomy\n* Pregnancy\n* Suspicious or confirmed gastrointestinal obstruction or gastrointestinal hemorrhage or gastrointestinal perforation\n* Epilepsy or currently use of anti-epileptic drug\n* Acute CNS infection or severe brain injury\n* Parkinson's disease\n* Confirmed or suspected pheochromocytoma\n* History of tardive dyskinesia, history of methemoglobinemia.","ALL","18 Years",{"count":56,"type":57},86,"ESTIMATED","INTERVENTIONAL",[60],"PHASE4","A prospective randomized controlled trial included 86 patients in medicine ward who were diagnosed with feeding intolerance, defined as having a gastric residual volume greater than 200 ml. The patients were randomly assigned to two treatment groups: one receiving enteral metoclopramide and the other receiving intravenous metoclopramide. The primary outcome was the gastric residual volume at 72 hours after treatment. The secondary outcome was gastric residual volume at 24 hours and 7 days after treatment, administered-to-prescribed volume at 72 hours after treatment, the administered-to-target energy ratio and the administered-to-target protein ratio at 96 hours after treatment, the nutrition status evaluated by the Nutrition Alert Form at 7 days after treatment, incidence of adverse events (arrhythmia, pneumonia, diarrhea, vomiting, aspiration), length of hospital stay, ICU length of stay and in-hospital mortality.",[63],"Feeding Intolerance",[65,66,67],"gastric residual volume","metoclopramide","itopride","NOT_YET_RECRUITING","2025-06-19",{"date":71,"type":72},"2025-06-22","ACTUAL",{"date":74,"type":57},"2025-07-01",{"date":76,"type":57},"2026-09-30",{"name":5,"class":6}]